NCT07038733 Investigation of Lymph Node Biology in Kidney Cancer
| NCT ID | NCT07038733 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Yale University |
| Condition | Renal Cell Carcinoma (RCC) |
| Study Type | INTERVENTIONAL |
| Enrollment | 33 participants |
| Start Date | 2026-01-30 |
| Primary Completion | 2030-12 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 33 participants in total. It began in 2026-01-30 with a primary completion date of 2030-12.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The purpose of this pilot study is to investigate the phenotype, anti-tumor effector functions, and TCR repertoire of T cells isolated from patient tumor draining lymph nodes (TDLNs) to understand T cell priming and trafficking patterns in Renal Cell Carcinoma (RCC). Data and biospecimen collected will be used for current and future research projects involving the study of kidney cancer biology and related medical conditions. Investigators will use this valuable resource to ask clinically relevant translational questions that pertain to biomarker discovery/validation, identification of novel therapeutic targets, and to better understand the genetic and biological basis of the various kidney cancers.
Eligibility Criteria
Inclusion Criteria: Candidates for inclusion include adult patients with either a known or suspected kidney cancer referred to Yale Genitourinary Oncology providers in the Yale Urology, Medical Oncology and Radiation Oncology or Nephrology Departments. These individuals will be receiving clinical evaluation/medical treatment/surgery/procedures at Yale New Haven Hospital or the Smilow Cancer Hospital. Participant eligibility will be determined by study investigators and will be offered protocol details. Interested participants will be invited to participate by study investigators. Consent will be obtained by study investigators or other authorized study personnel. Any potential adult participants with known or suspected kidney cancers with a renal mass who are patients of non-study physicians will be invited to participate by study personal only with the approval of their treating physician. Exclusion Criteria * Participants under the age of 18. Children will not be enrolled on the study. * Participants known to be pregnant or actively breastfeeding. * Iodine allergy hypersensitivity.
Contact & Investigator
David Braun, MD
PRINCIPAL INVESTIGATOR
Yale University
Frequently Asked Questions
Who can join the NCT07038733 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Renal Cell Carcinoma (RCC). Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT07038733 currently recruiting?
Yes, NCT07038733 is actively recruiting participants. Contact the research team at stephanie.ladd@yale.edu for enrollment information.
Where is the NCT07038733 trial being conducted?
This trial is being conducted at New Haven, United States.
Who is sponsoring the NCT07038733 clinical trial?
NCT07038733 is sponsored by Yale University. The principal investigator is David Braun, MD at Yale University. The trial plans to enroll 33 participants.